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Abstract
Background: Tackling multidrug-resistant Escherichia coli requires evidence from One Health studies that capture
numerous potential reservoirs in circumscribed geographic areas.
Methods: We conducted a survey of extended β-lactamase (ESBL)-producing E. coli isolated from patients, canals
and livestock wastewater in eastern Thailand between 2014 and 2015, and analyzed isolates using whole genome
sequencing.
Results: The bacterial collection of 149 isolates consisted of 84 isolates from a single hospital and 65 from the
hospital sewer, canals and farm wastewater within a 20 km radius. E. coli ST131 predominated the clinical
collection (28.6%), but was uncommon in the environment. Genome-based comparison of E. coli from infected
patients and their immediate environment indicated low genetic similarity overall between the two, although
three clinical–environmental isolate pairs differed by ≤ 5 single nucleotide polymorphisms. Thai E. coli isolates
were dispersed throughout a phylogenetic tree containing a global E. coli collection. All Thai ESBL-positive E.
coli isolates were multidrug resistant, including high rates of resistance to tobramycin (77.2%), gentamicin
(77.2%), ciprofloxacin (67.8%) and trimethoprim (68.5%). ESBL was encoded by six different CTX-M elements and
SHV-12. Three isolates from clinical samples (n = 2) or a hospital sewer (n = 1) were resistant to the carbapenem
drugs (encoded by NDM-1, NDM-5 or GES-5), and three isolates (clinical (n = 1) and canal water (n = 2)) were
resistant to colistin (encoded by mcr-1); no isolates were resistant to both carbapenems and colistin.
Conclusions: Tackling ESBL-producing E. coli in this setting will be challenging based on widespread
distribution, but the low prevalence of resistance to carbapenems and colistin suggests that efforts are now
required to prevent these from becoming ubiquitous.
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Background
The global spread of multidrug resistant bacteria is a
major threat to human health. This includes drug-
resistant Escherichia coli, a leading cause of blood-
stream and urinary tract infections [1]. Extended
spectrum β-lactamase (ESBL)-producing E. coli are
capable of hydrolysing numerous antibiotics,
including third-generation cephalosporins [1]. This
impacts on patient outcome, since infection with
ESBL-producing E. coli is associated with higher
mortality, longer length of hospital stay and in-
creased costs compared to infection with antibiotic-
susceptible E. coli [2]. The challenge to successful
therapy has further increased following the emer-
gence of multidrug-resistant isolates with acquired
resistance to the carbapenem drugs and more
recently to colistin, a drug of last resort for
multidrug-resistant infections [3, 4]. Transferrable
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colistin resistance is mediated by mcr-1 or mcr-2 car-
ried on a plasmid, and has been detected in E. coli
isolated in Europe, Africa and Asia [4, 5].
Tackling multidrug-resistant bacteria requires an un-
derstanding of their reservoirs and routes of spread. E.
coli are normal gut commensals for humans and other
animals, including livestock, and can be isolated from
food and the environment [6, 7]. Studies are increas-
ingly reporting isolation of multidrug-resistant E. coli
from livestock, such as chickens, ducks, pigs and cattle
in Asia (China, South Korea and Lebanon) and Europe
(the UK and the Netherlands), as well as meat and the
environment [8–13]. ESBL-producing E. coli can also
persist in the farm environment for prolonged periods
[14], and become concentrated in the surrounding en-
vironment through repeated contamination with farm
wastewater [11]. Water may also provide a mechanism
for the further dissemination of ESBL-producing E. coli
across more extended distances. This could increase
the risk of human acquisition through the consump-
tion of contaminated drinking water [15].
The need to understand the relationship between E.
coli from different reservoirs through One Health stud-
ies is well known, but requires a discriminatory bacter-
ial typing technique. The increasing application of
whole genome sequencing brings a level of discrimin-
ation and information on relatedness and resistance
mechanisms that surpass previous typing methods [16].
This has been used to compare the whole genomes of
environmental, commensal and pathogenic E. coli to
understand their ecology and speciation [17]. Several
studies have used genome sequencing to characterize
multidrug-resistant E. coli with a particular focus on
ST131, which has become a dominant clinical clone
worldwide [18–20]. The use of whole genome sequen-
cing in countries engaged in intensive livestock farm-
ing, which have been proposed to be at high risk for
the emergence of drug resistance, is important. One
such country is Thailand, which is a major producer
and exporter of chickens. A recent study reported that
nearly 78% of E. coli isolated from pig and broiler
carcass samples from slaughterhouses in eastern
Thailand were multidrug resistant [21]. In addition,
ESBL-producing E. coli was highly prevalent in samples
from healthy adults (76%), healthy pigs (77%) and
broiler chickens (40%), and in water samples collected
from farms (33%) and canals in central Thailand (25%)
[7]. A limitation of this study was that genotyping was
not performed to examine strain relatedness or define
the mechanisms of resistance. Here, we describe the
findings of a survey of ESBL-producing E. coli isolated
from patients, canals and livestock wastewater in a de-
fined region of eastern Thailand in which isolates were
evaluated using whole genome sequencing.
Methods
Study design and bacterial isolates
The bacterial collection consisted of 149 ESBL-positive
E. coli isolated between 2014 and 2015. Clinical iso-
lates (n = 84) were from consecutive positive samples
processed by the diagnostic microbiology laboratory at
Bhuddhasothorn hospital, Chachoengsao province,
eastern Thailand between December 2014 and April
2015. Date of isolation and sample type were recorded,
and only one isolate per patient was included. Isolate
details are shown in Additional file 1: Table S1. Bacter-
ial isolates were initially identified and susceptibility
testing performed using Standard Operating Proce-
dures supplied by the Department of Medical Science,
Ministry of Public Heath, Thailand and Clinical and
Laboratory Standards Institute (CLSI) guidelines
(M100-S24 and M100-S25), respectively. Species was
subsequently confirmed using matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS; Biotyper version 3.1, Bruker
Daltonics, Coventry, UK). Antimicrobial susceptibility
testing was repeated using the N206 card on the Vitek
2 instrument (bioMérieux, Marcy l’Étoile, France)
calibrated against EUCAST breakpoints, and these
results used during the analysis. E-test (bioMérieux,
Marcy l’Étoile, France) was used when further
verification was required.
Environmental isolates (n = 65) were obtained
through a cross-sectional survey between January 2015
and February 2015 described previously [22]. In brief,
wastewater samples were collected from 27 canals and
11 farms within a 20 km radius of Bhuddhasothorn
hospital. The farms reared pigs (n = 2), chickens (n = 6),
ducks (n = 2) and both chickens and ducks (n = 1),
where samples were collected from gullies that drained
waste from animal housing. The geographical position
of each sampling site was recorded using GPSMAP
60CSx (Garmin, Taiwan). A further two wastewater
samples were taken from the Bhuddhasothorn hospital
wastewater treatment system (one pre-treatment and
one post-treatment water sample). Maps of the study
region were created using ArcGIS software version
10.3.1.
Wastewater processing and bacterial identification
Samples were processed by filtration onto membranes
as described previously [22], which were incubated on
ESBL Brilliance agar (Oxoid, Basingstoke, UK) for 48 h
at 35 °C in air. Up to ten colonies suspected to be E.
coli based on colour were picked and screened for
ESBL expression using a phenotypic confirmation test
based on CLSI guidelines (M100-S25). Species and
antimicrobial susceptibility testing were confirmed
using MALDI-TOF MS and Vitek 2, as described
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above. All bacterial isolates were stored at −80 °C in
trypticase soy broth with 20% glycerol.
Whole genome sequencing and data analysis
DNA extraction, sequencing and assembly of reads
were performed as described previously [23]. Sequen-
cing was performed on an Illumina HiSeq2000.
Genomes were assembled using Velvet with the im-
provements described previously [24]. Details of reads,
numbers of contigs and N50 are provided in
Additional file 2: Table S2. Multilocus sequence types
(MLST) were identified from the sequence data using
the Achtman scheme and an in-house script (https://
github.com/sanger-pathogens/mlst_check). Sequence
data have been deposited in the European Nucleotide
Archive (ENA; http://www.ebi.ac.uk/ena) under the
individual accession numbers given in Additional file 2:
Table S2.
The pan-genome was estimated for the 149 study ge-
nomes using Roary, with a minimum percentage iden-
tity for blastp of 90%, and an alignment created of all
core genes (present in 99% of isolates) [25]. Single nu-
cleotide polymorphisms (SNPs) in the core genes were
extracted and used to construct a maximum likelihood
tree using RAxML with 100 bootstraps and a midpoint
root. Additionally, the study genomes were contextua-
lised against a global collection. Sequence data for 514
E. coli isolates reported previously [26–28] were down-
loaded from the ENA and the Wellcome Trust Sanger
Institute Pathogen Genomics pipeline and annotated
using Prokka. The 514 global genomes were combined
with the 149 study genomes and the pan-genome esti-
mated using Roary. SNPs in the core genes were used
to construct a maximum likelihood tree as above.
To place the 26 ST131 study isolates into a global
context, sequence data for 319 ST131 isolates reported
previously [18, 19, 29] were downloaded from the ENA.
These, together with the 26 ST131 study genomes, were
mapped to E. coli NTCC13441 (accession number
LT632320-LT632321) using SMALT (http://www.san-
ger.ac.uk/science/tools/smalt-0). All isolates had greater
than 95× coverage. Mobile genetic elements were identi-
fied and removed as described previously [30]. Recom-
bination was removed using Gubbins [31]. SNPs were
identified and used to construct a maximum likelihood
tree. Four isolates from Price et al. [32] and three iso-
lates from Stoesser et al. [33] were filtered out by Gub-
bins, leaving a total of 312 external and 26 study isolates
in the phylogeny. FimH typing was performed by in
silico PCR with previously published primers [34] and
the resulting products compared to the sequences of
known FimH types [35] using blastn. The H30R and
H30Rx sub-clones were classified by H30Rx-specific
SNPs as described previously [18] using in silico PCR.
Identification of antimicrobial resistance determinants,
virulence factors and plasmids
To detect acquired genes encoding antimicrobial re-
sistance, a manually curated version of the ResFinder
database (compiled in 2012) was used [36]. Sequences
were compared to this as described previously and
genes with > 90% identity match were classified as
present. The presence of the mcr-1 and mcr-2 genes
was detected using in silico PCR with previously published
primers [5, 37]. Sequences of the seven CTX-M genes
identified here (CTX-M14-1 (JF701188), CTX-M14-48
(AJ416341), CTX-M15-23 (DQ302097), CTX-M24-8
(EF374096), CTX-M27-1 (EU916273), CTX-M55-2
(GQ456159) and CTX-M65-2 (GQ456158)) were
downloaded from the ENA and a phylogeny created using
FastTree [38]. Putative virulence genes were collated from
the Virulence Factors of Pathogenic Bacteria Database
(http://www.mgc.ac.cn/VFs/; n 284). The presence of
virulence factors was determined using an in-house script
(https://github.com/simonrharris/map_resistome) with
genes classed as present if there was a match with > 90%
length and > 90% identity. Statistical analyses were
performed using Fisher’s exact test with a p value of 0.05.
Results
Isolation of ESBL-producing E. coli from patients and the
environment
A cross-sectional survey of canals and untreated waste
from farms and a hospital in Chachoengsao province,
Thailand led to the recovery of 65 ESBL-positive E.
coli. Fifty-six were isolated from canals, three from
pre-treated hospital wastewater and six from wastewa-
ter from four different farms (Fig. 1). A longitudinal
survey of ESBL-positive E. coli isolated from clinical
samples from the microbiology laboratory at Bhuddha-
sothorn hospital between December 2014 and April
2015 led to the identification of 84 isolates from blood
(21 isolates), urine (39), pus (23) and sputum (1).
Sequence types (STs) were identified from the whole
genome sequence data. Taken together, the 149 ESBL-
positive E. coli isolates were assigned to 72 STs,
although the clinical isolate collection (84 isolates, 30
STs) was less diverse than the environmental isolate
collection (65 isolates, 53 STs). The prevalence of the
eight most frequent STs identified in each of the
clinical or environmental collections is shown in
Additional file 3: Figure S1. ST131 was the predomin-
ant ST in the clinical collection (24/84, 28.6%), whilst
no single ST predominated in the environmental
collection.
Antibiotic resistance
Phenotypic antibiotic susceptibility and the presence of
genes encoding antibiotic resistance were determined for
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all 149 ESBL-positive E. coli, the results of which are sum-
marized in Figs. 2 and 3. All isolates were multidrug resist-
ant (phenotypic resistance to three or more drug classes)
[39]. Resistance to the carbapenem drugs was identified in
two clinical isolates (resistant to ertapenem and mero-
penem), and one from hospital wastewater (intermedi-
ate resistance to ertapenem (MIC 0.75 μg/mL) but
susceptible to meropenem (MIC 0.5 μg/mL)). The two
carbapenem-resistant clinical isolates contained either
New Delhi metallo-β-lactamase-1 (NDM-1; ST44) or
NDM-5 (ST46), and the hospital wastewater isolate
contained Guiana extended-spectrum β-lactamase-5
(GES-5; ST1585) (Fig. 3a).
The genetic basis for ESBL production is shown in
Fig. 3. A total of 149 CTX-M elements identified in 147
isolates were resolved into six different elements, with
CTX-M-55 (40.9%) the most common (Fig. 3b). SHV-12
type β-lactamase was present in three isolates (one clin-
ical and two environmental), one of which was also posi-
tive for CTX-M-14. CTX-M-55 was the most prevalent
Fig. 1 Map of sampling. Geographical location of sampling points. Left: map indicating the position of Chachoengsao province in East Thailand
(white area, Chachoengsao province; yellow areas, other Thai provinces). Right: map indicating environmental sampling points in individual main
districts (amphoe) within Chachoengsao province. Black symbols, positive for ESBL-positive E. coli; white symbols, ESBL-positive E. coli not isolated.
Map created using ArcGIS software by Esri
Fig. 2 Phenotypic antimicrobial resistance for ESBL-producing E. coli from clinical and environmental sources. The percentage of clinical (n = 84)
and environmental (n = 65) isolates resistant to each antibiotic tested
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CTX-M in clinical isolates (41.7%), whilst CTX-M-14
was the most prevalent in environmental isolates
(44.6%). The proportions of CTX-M elements in clinical
and environmental isolates are shown in Fig. 3c and a
phylogeny of the CTX-M genes is shown in Additional
file 3: Figure S2. Two variants of CTX-M-14 were identi-
fied that differed by one SNP and corresponded to CTX-
M-14-1 (n 31; GenBank accession number JF701188)
and CTX-M-14-48 (n 17; GenBank accession number
AJ416341), respectively. In addition, two clinical isolates
and one environmental isolate contained two different
elements (Additional file 1: Table S1). Study isolates were
screened for the presence of mcr-1 and mcr-2 encoding
resistance to colistin, which detected mcr-1 in three iso-
lates (one clinical and two environmental from inde-
pendent canals; Fig. 3a). Phenotypic resistance to colistin
was confirmed using the E-test; MIC values of the three
isolates were 4, 3 and 8 μg/mL.
Phylogenetic analysis of ESBL-E. coli from Thailand
A maximum likelihood tree of the 149 ESBL-positive E.
coli was created based on 227,154 SNPs in the 2682 core
genes (Fig. 3a). The majority of clinical and
environmental isolates resided on distinct branches of
the phylogenetic tree, with environmental isolates show-
ing a greater level of diversity than the clinical isolates.
However, 11/72 STs contained both clinical and environ-
mental isolates, and a pairwise comparison of SNPs in
the core genes revealed that these were closely related
(3–23 SNPs, median 9 SNPs) in 6/11 STs (ST131,
ST2003, ST354, ST38, ST405 and ST410). Three pairs of
clinical–environmental isolates differed by no more than
five SNPs, whilst an additional 18 pairs of isolates dif-
fered by less than 25 SNPs. The environmental isolates
were all from canals within 0.5 to 5.2 km of the hospital
(median 2.3 km) with the exception of one isolate, which
was taken from the hospital wastewater treatment sys-
tem and was nine SNPs different from a clinical isolate.
The phylogeny of the 149 study genomes was contex-
tualized by combining these with 514 E. coli genomes
from a global collection. A maximum likelihood tree
was created based on 222,900 SNPs in the 1983 core
genes identified across the 663 isolates (Additional file
3: Figure S3). Thai E. coli isolates were distributed
across the E. coli species population, suggesting a high
level of diversity in the Thai E. coli population. Of note,
A B
C
Fig. 3 Distribution of ESBL, NDM and mcr-1 genes in E. coli from East Thailand. a Left: maximum likelihood tree of 149 study isolate genomes based on
SNPs in the core genome. Scale bar indicates ~ 10,000 SNPs. The columns describe the origin (red, clinical; blue, canal; pink, farm wastewater; grey,
untreated hospital sewage), ESBL elements (white, absent; yellow, CTX-M-55; purple, CTX-M-14; red, CTX-M-15; light blue, CTX-M-27; pink, CTX-M-24;
brown, CTX-M-65; orange, SHV-12; black, multiple ESBL elements) and data for SHV-12 (blue, absent; red, present), NDM (blue, absent; red, NDM-1; orange,
NDM-5), GES-5 (blue, absent; red, present), and mcr-1 (blue, absent; red, present). Right: the top ten multilocus sequence types. b Prevalence of ESBL
elements (CTX-M and SHV-12 variants) in 149 study isolates. Three isolates contained multiple elements (CTX-M-15 and CTX-M-27, CTX-M-27 and
CTX-M-55, and CTX-M-14 and SHV-12, respectively). c Percentage of each CTX-M variant and SHV-12 in 84 clinical versus 65 environmental isolates
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one isolate from Thailand was two SNPs different from
isolates from neighbouring Cambodia.
Phylogenetic analysis of ST131 ESBL-producing E. coli in
Thailand
Assignment of the 26 ST131 study isolates to fimH types
revealed that the majority of Thai isolates belonged to
H30 (76.9%) or H41 (19.2%). All 20 H30 isolates were
resistant to ciprofloxacin and contained a CTX-M elem-
ent (70% CTX-M-14, 25% CTX-M-27, 5% CTX-M-15).
The majority of H30 isolates (19/20) belonged to the
H30R subclone described by Price et al., with only one
H30 isolate belonging to the H30Rx subclone. The
ST131 study isolates were compared with a global
collection of E. coli ST131 [18, 19, 29] (Fig. 4). The ma-
jority of Thai ST131 E. coli from this study belonged to
two clusters (cluster 1 (n = 19) and cluster 2 (n = 4)).
Cluster 1 belonged to H30R and contained isolates from
Laos (n = 9), Cambodia (n = 3), Australia (n = 2), the
USA (n = 2), Canada (n = 1), Germany (n = 1) and
Taiwan (n = 1), interspersed with the 19 study isolates
and two isolates from a previous study [29] from
Thailand. An analysis of pairwise SNP differences re-
vealed 14–92 SNPs between the Thai and global isolates
in this cluster. Additionally, cluster 1 contained two en-
vironmental isolates from Thailand, obtained from inde-
pendent canals, which were 19 and 38 SNPs from the
nearest clinical isolates, both from Thailand. This cluster
could be further divided into two groups based on the
phylogeny and presence of CTX-M elements. One group
(C1a) contained seven Thai isolates (five from this study),
three Laotian, one Cambodian and two Australian isolates
harbouring CTX-M-27, and an additional isolate from
Laos harbouring CTX-M-24. The second group (C1b)
contained 14 Thai, two Cambodian and five Laotian iso-
lates harbouring CTX-M-14 (16 with CTX-M-14-1, three
with CTX-M-14-48 and two with a novel CTX-M-14 vari-
ant). This suggests that these lineages may have acquired
their CTX-M elements prior to spreading between coun-
tries. Additionally, both groups (C1a and C1b) contained
CTX-M-negative isolates from Germany and/or the US
that were basal to the CTX-M-positive isolates in the
Fig. 4 E. coli ST131 comparison. Maximum likelihood tree of the 26 study ST131 isolates and 312 global ST131 isolates mapped against the
reference strain E. coli NTCC13441. Coloured rings from the inside out indicate country of origin, fimH type, CTX-M type and study isolates (black),
respectively. Branches coloured blue indicate the major clusters of Thai isolates from this study (C2; 11 o’clock in the figure) or Thai isolates from
this study clustered with phylogenetically related isolates from other countries (C1; 5 o’clock in the figure). Scale bar indicates 100 SNPs
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group. The remaining isolates in cluster 1 that did not be-
long to one of these two groups were a CTX-M-negative
isolate from Taiwan and a single isolate from Canada that
was CTX-M-14-positive and was located basal to the
whole cluster. Cluster 2 consisted of four isolates from
Thailand and belonged to the H41 sub-clone, which
contained isolates from Laos (n = 8), Thailand (n = 7),
the United Kingdom (n = 7), the USA (n = 5), Cambodia
(n = 2), Australia (n = 2), Canada (n = 2), New Zealand
(n = 1), Spain (n = 1) and Taiwan (n = 1) (Fig. 4). The
four Thai isolates residing in cluster 2 contained CTX-
M-27 alone (three isolates), or both CTX-M-27 and
CTX-M-55 (one isolate).
Characterisation of mcr-1 and carbapenamase-encoding
plasmids
We investigated the genetic context of the colistin and
carbapenemase resistance genes detected in the study
isolates by comparing the contigs containing these genes
to the GenBank database. The highest matches to the
contigs containing mcr-1 were equal matches to E. coli
plasmids pECJS-59-244, pS38 and EC2-4 for one of the
canal isolates; and S. enterica subsp. diarizonae strain
11-01854 and 11-01853 plasmids for the clinical isolate
and the second canal isolate (Additional file 4: Table S3).
The three highly related E. coli plasmids have been re-
ported previously as carrying the mcr-1 gene, and were
isolated in China, Switzerland and Malaysia. Addition-
ally, it has been reported that mcr-1 in three E. coli from
commercial farms in China were carried on plasmids
with a similar backbone to plasmid 11-01854 [40]. The
contig containing NDM-1 was best matched to E. coli
plasmid pNDM-ECS01, which has been described previ-
ously as carrying NDM-1 in ST131 E. coli and Klebsiella
pneumoniae in Thailand [41]. The contig containing
NDM-5 had equal matches to E. coli plasmids
pC06114_1 and pGUE-NDM, which carry NDM-1, and
K. pneumoniae plasmids pCC1409-1 and pCC1410-1,
which carry NDM-5 and were identified in Korea after
transfer of a patient from the United Arab Emirates [42].
Finally, the contig containing GES-5 was best matched
to E. coli plasmid pHKU1, which was described in the
context of fosfomycin resistance in E. coli and to our
knowledge has not been reported previously to carry
GES-5. However, only 40% of the contig matched plas-
mid pHKU1, indicating differences in the genetic con-
tent (Additional file 4: Table S3). Overall these results
indicate that plasmids carrying mcr-1 in Thailand may
be globally disseminated, and those carrying carbapena-
mase resistance genes could have originated from other
countries in Asia or the Middle East. The finding of
mcr-1 on a potentially novel plasmid indicates further
dissemination of mcr-1 in the plasmid population.
Virulence genes
Of the 284 virulence genes investigated, 153 were
detected at least once in the 149 study isolates.
Analysis of the distribution of virulence factors across
STs indicated that there was a higher prevalence of
virulence genes in ST131. To further examine this,
we compared the prevalence of each virulence factor
in ST131 (n = 26) and non-ST131 (n = 123). A total of
36 virulence genes were significantly more common
in ST131 (all < 0.0001 except for fim genes, p < 0.05)
(Additional file 3: Figure S4); 35 of these associations
have not been reported previously (the exception be-
ing sat) [43–46]. Twelve virulence genes were signifi-
cantly less common in ST131 isolates (p value < 0.05),
including four genes (entD, espX1, espX5 and espL1)
present in over 79% of non-ST131 isolates but absent
in ST131 isolates (Additional file 3: Figure S4).
Discussion
This study has demonstrated that Thai ESBL-positive E.
coli isolates are genetically diverse, with isolates dispersed
throughout a phylogenetic tree containing a global collec-
tion of E. coli. Thai isolates cultured from the environ-
ment were more genetically diverse than those from Thai
patients, and a core genome comparison indicated that
ESBL-positive E. coli from humans and the environment
(including farms) were broadly distinct, although there
was evidence for some highly related bacterial pairs. All of
the Thai ESBL-positive E. coli isolates were multidrug re-
sistant, including high rates of resistance to aminoglyco-
sides, fluoroquinolones and trimethoprim. A small
minority of isolates were also resistant to the carbapenem
drugs (encoded by NDM-1, NDM-5 or GES-5) or to colis-
tin (encoded by mcr-1), but no isolates were resistant to
both the carbapenem drugs and colistin. Of note, isolates
resistant to the carbapenem drugs were only isolated
from clinical samples or a hospital sewer, while isolates
resistant to colistin were identified from both clinical
samples and canal water.
The isolation of NDM-1-positive E. coli from Thailand
has been reported previously from urine samples
cultured from patients with urinary tract infection at
Srinagarind Hospital, Khon Kaen province in 2011 [47].
To our knowledge, this is the first report of both NDM-
5 and GES-5 in Thailand, but NDM-5-positive E. coli
has been isolated from humans in numerous countries,
including the United Kingdom in 2011 [48], and in
China, Algeria, Japan, USA, Denmark, Australia, Spain,
Egypt and South Korea between 2014 and 2016 [49–56].
NDM-5-positive E. coli has also been identified from a
domestic animal in Algeria [57]. GES-5-positive E. coli
was first documented in Greece in 2004 in a clinical iso-
late with low level resistance to carbapenem drugs [58].
The first report of mcr-1-positive E. coli was from China
Runcharoen et al. Genome Medicine  (2017) 9:81 Page 7 of 11
in 2015 but there is increasing evidence that the mcr-1
gene had been circulating in Asia prior to this, including
in Thailand based on the retrospective identification of
mcr-1-positive E. coli that was originally isolated in 2011
[4, 37]. Blast comparisons performed during our study
of contigs containing mcr-1 and genes encoding carba-
penem resistance were consistent with this being plas-
mid-mediated. Genetic characterisation of CTX-M genes
was notable for the diversity in elements identified, with
six elements identified but with CTX-M-55 being the
most common and present in clinical and environmental
isolates. By contrast, the proportion of other elements (for
example, CTX-M-15 and CTX-M-27) varied considerably
between human and environmental isolates.
E. coli ST131 was the predominant clone associated
with human disease in Thailand and accounted for almost
one-third of isolates, although was uncommonly isolated
from the environment. This lineage is frequently
multidrug-resistant, has become globally disseminated
and is a well-known cause of human disease [59, 60]. We
identified 36 virulence factors that were over-represented
in ST131 compared with non-ST131 isolates. This com-
parison should be interpreted with caution since this was
underpowered (26 ST131 isolates versus 123 non-ST131
isolates), and the comparison of a single clone with a gen-
etically heterogeneous second group is potentially
problematic. However, differences in gene contents be-
tween ST131 and other lineages is consistent with previ-
ous studies, which have reported over-representation in
ST131 of genes associated with adhesion (afa/dra, fimH,
papA and iha,), invasin (ibeA), iron acquisition (fyuA and
iutA), toxins (sat and aer), protectins (kpsMII, kpsMIII,
K2, K5 and ompT) and other functions (usp, traT and
malX) [43–46, 61].
Our findings add to the increasing body of evidence that
ESBL-positive E. coli is ubiquitous in Thailand. A recent
study reported that ESBL-producing E. coli could be iso-
lated from three-quarters of healthy Thai people tested
and was also common in livestock, which suggests that
this has become established in humans and their food
chain [7]. There is also direct evidence for human con-
sumption of food containing ESBL-producing E. coli,
which was isolated from pre-cooked and cooked meat col-
lected from markets in Bangkok, Thailand in 2012–2013
[7]. Furthermore, there is evidence for global dissemin-
ation since nearly 20% of a sample consisting of a range of
fresh vegetables imported into Switzerland from Thailand
in 2014 was positive for ESBL-producing E. coli [62]. This
is having an impact on human health in Thailand based
on the findings of a retrospective study conducted in nine
public hospitals in northeast Thailand [63]. The pro-
portions of community-acquired E. coli bacteraemia
caused by E. coli non-susceptible to extended-spectrum
cephalosporins rose from 5 to 23% between 2004 and
2010, while the proportions of healthcare-associated
and hospital-acquired E. coli bacteraemia caused by E.
coli non-susceptible to extended-spectrum cephalospo-
rins were high (44 and 52%, respectively) with no sig-
nificant change over time [63]. Mortality was higher in
patients with multidrug-resistant E. coli bacteraemia
compared with non-multidrug-resistant E. coli bacter-
aemia [63], indicating the human cost of this problem.
Conclusions
Our genome-based study adds to the epidemiological
and phenotypic data for ESBL-positive E. coli in
Thailand. There was some evidence for highly related E.
coli between infected patients and their immediate envir-
onment, and we identified a plethora of genes encoding
drug resistance to broad-spectrum antibiotics used to
treat Gram-negative infections. The extent to which
ESBL-positive E. coli is distributed in humans, the envir-
onment and the food chain, the diversity of elements en-
coding ESBL and the epidemiological rise in the
proportion of multidrug-resistant E. coli causing human
disease indicates that this has gathered pace over the
past decade. ESBL genes likely provide a fitness advan-
tage to E. coli belonging to numerous different lineages,
both in the environment and in clinical settings. Further-
more, these genetic elements are likely to be present in a
range of additional Gram-negative bacterial species.
Reversing the clock on ESBL in this setting may prove
extremely difficult, but our finding of a comparatively
low prevalence of mobile genes encoding resistance to
the carbapenem drugs and colistin suggests that efforts
are now required to prevent these from also becoming
ubiquitously distributed.
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